Case histories
The table shows details offive patients with sarcoidosis seen by us during 1%9-86. In each case the diagnosis ofsarcoidosis was based on both the clinical findings and histological evidence ofnon-caseating epithelioid cell granulomas. The mean age of the patients at the time of diagnosis was 55 (range 42-65). In four patients myeloma developed several years after the diagnosis of sarcoidosis; in one both diagnoses were made at the same time. The duration ofsarcoidosis was more than two years in three patients (cases 1, 2, and 4), and sarcoidosis was considered to be active at the time of diagnosis of myeloma in two (cases 2 and 5). Two patients (cases 1 and 2) had been treated with steroids.
All patients met the diagnostic criteria for multiple myeloma. Four patients (cases 1-4) were treated with cytotoxic drugs and the other (case 5) was followed up without treatment. Four patients survived, but the other (case 3) died in 1985, four years after the diagnosis of myeloma.
Comment
All our patients showed features consistent with sarcoidosis and were not thought to have had a sarcoidosis like reaction, such as has been described in association with malignant tumours, among them lymphoma and myeloma. In four of the cases the long time interval between the diagnoses (three to 12 years) increases the chance that these patients had two separate disease processes. In the one patient who presented with sarcoidosis and myeloma at the same time it is of course conceivable that both disorders were due to the same disease process.
The mean age of our patients at the time of diagnosis of sarcoidosis was appreciably higher than the average age at which sarcoidosis is diagnosed. We thus agree with Brincker that it is the chronic active type of sarcoidosis that develops in middle aged patients that is associated with the subsequent development of neoplastic disease. 2 Proof of a causal rather than a merely coincidental association between sarcoidosis and myeloma may be obtained only by prospective epidenliological studies. Both diseases, however, are comparatively rare, the incidence of sarcoidosis in Finland varying from 5 to 21/100 000 and that of myeloma being about 3/100 000. On the basis of these figures, the expected number of cases of both sarcoidosis and myeloma in the Finnish population (somewhat below five million) during a 10 year follow up is less than 0 3, which suggests a very low chance of the two disorders occurring by coincidence.
Although the aetiology of multiple myeloma is unknown, evidence suggests that chronic stimulation of the immune system may be a predisposing factor, presumably in combination with genetic or viral factors.5 Sarcoidosis is a chronic granulomatous disease, also of unknown aetiology, that has pathogenetic features that may predispose to the development of lymphoproliferative diseases, such as myeloma. In sarcoidosis activated T helper/inducer lymphocytes in the sites of inflammation cause a polyclonal stimulation of B lymphocytes, which may result in hypergammaglobulinaemia. Prolonged stimulation of B lymphocytes together with a disturbance in the regulation ofthe immune system might result in the development of an autonomous plasma cell clone producing a monoclonal immunoglobulin'. Alternatively, a common primary immunological derangement or a common aetiological factor might underlie the development of both sarcoidosis and myeloma in certain people.
